Empower commences COVID-19 RT-PCR testing supported by Kai Medical Laboratory to process daily testing requirements as part of a “Back to Work” and “Back to School” campaign
VANCOUVER BC / ACCESSWIRE / September 10, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower.
The programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.
RT-PCR Testing can be booked via: https://www.sunvalleyhealth.com/covid-19-test-book-now/
Currently Kai Medical Laboratory has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine.
“Launching our RT-PCR testing programs utilizing the capability of Kai Medical Labs gives us the ability to access massive testing volume not only in Arizona, but nationwide in the U.S.” said Steven McAuley, Empower’s Chairman & CEO. “Our team at Sun Valley Health has created numerous strategic marketing campaigns to drive awareness and testing volume, leveraging our supply chain improvements with increased profit margins.”
Many schools and universities are now requiring students and teachers to provide RT-PCR testing results prior to returning to campus. Our nasal or throat swab RT-PCR testing program allow students and teachers to quickly be tested and receive results from a Clinical Laboratory Improvement Amendments (CLIA), accredited laboratory in only 24 – 48 hours.
Businesses need a stable workforce, and must be quick to isolate employees with any symptoms. Our RT-PCR testing allows employees to be tested quickly and receive results within 24 – 48 hours, giving the employee and the employer the opportunity to activate non-contagious employees and safely return to work!
Travelers are also discovering demands to get a RT-PCR test and provide the result upon check-in at the airport. The reports are required to be no more than 3 days old. Our testing program provides accurate results within 24-48 hours, giving the patient a document that can make the difference in being able to travel.
https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-testing.html
An RT-PCR assay is a viral molecular test to detect active infection directly in a patient’s RNA genetic sequence. An RT-PCR swab test is considered the gold-standard for testing & diagnosing active viral infections and should be used for anyone who has symptoms or known exposure to COVID-19. These tests are renowned for high sensitivity and high specificity.
(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.
USA COVID-19 Data as at September 9, 2020
TOTAL CASES: 6,310,663
TOTAL DEATHS: 189,147
CASES IN LAST 7 DAYS: 262,971
ARIZONA as at September 9, 2020
CONFIRMED CASES: 204,239
PROBABLE CASES: 1,806
TOTAL CASES: 206,045
CASES IN LAST 7 DAYS: 3,703
CASES/100K: 2,873
DEATHS/100K: 72
TEXAS as at September 9, 2020
TOTAL CASES: 641,791
CASES IN LAST 7 DAYS: 24,458
CASES/100K: 2,236
DEATHS/100K: 47
ABOUT EMPOWER
Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.
ABOUT Kai Medical Laboratory
Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors: Dustin Klein
Director
[email protected]
720-352-1398
Investors: Steven McAuley
CEO
[email protected]
604-789-2146
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/605506/Empower-Clinics-Expands-COVID-19-Testing-Programs-by-Commencing-RT-PCR-Testing